坦克结合激酶1
封锁
裂谷1
癌症研究
免疫疗法
免疫学
激酶
生物
免疫检查点
医学
免疫系统
坏死性下垂
程序性细胞死亡
内科学
蛋白激酶A
细胞生物学
受体
MAP激酶激酶激酶
遗传学
细胞凋亡
作者
Michelle A. Kelliher,Katherine A. Fitzgerald
标识
DOI:10.1016/j.it.2023.01.009
摘要
Resistance mechanisms have curbed the potential of immune checkpoint blockade (ICB) therapies. Understanding mechanisms that contribute to this resistance should reveal new targets for combinatorial therapy. Tank-binding kinase 1 (TBK1) represents such a target. In recent work by Sun et al., inhibition of TBK1 restored the efficacy of such treatments by sensitizing tumors to RIPK1 kinase-dependent inflammatory cell death.
科研通智能强力驱动
Strongly Powered by AbleSci AI